Molecular Imaging, Biomarker & Probe Development (MBPD)

The Molecular Imaging, Biomarker & Probe Development Team excels in cutting-edge, innovative and scholarly scientific research on the design, synthesis, characterization, evaluation and validation of MR, PET, SPECT and optical imaging probes and technologies to fill unmet needs in healthcare and precision medicine.  The major goals of this interdisciplinary program are: to perform the highest quality scientific research in biomarker discovery and biomarker targeted imaging for oncology, cardiology, psychiatry, neurology and infectious diseases; to translate new imaging probes from bench-to-bedside for the biomarker specific diagnosis and individualized management of diseases; and to develop the next generation of biomarker and imaging probe scientists and young faculty. We serve Emory University, national and the international scientific communities with a rich environment and world class research expertise.

Laboratories and faculty in the Molecular Imaging, Biomarker & Probe Development team are currently working on PET tracers of alicyclic and branched chain amino acids for detecting intracranial and systemic tumors, cocaine analogs for imaging the dopamine, serotonin, and norepinephrine reuptake sites in neurodegenerative disease, psychiatric and addictive disorders, heterocyclic analogs for mapping CRF1, oxytocin and vassopressin receptors in psychiatric disorders, oligosaccharides for imaging bacterial infections and intercalating agents for imaging atherosclerotic plaque, multifunctional nanoparticles for targeted MRI, optical and photoacoustic imaging as well as image-guided drug delivery for biomarker validation and biomarker targeted diagnosis and treatment.  In addition, the metabolite imaging and metabolomics are applied for biomarker discovery.

mbpd1 mbpd3

Team Leaders

Mark Goodman, PhD
Hui Mao, PhD
Ephraim Parent, MD, PhD

Team Members